The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations

As China has become the world's second-largest economy and the largest developing country, its economy and market have assumed a prominent position in the Asia-Pacific region. The pharmaceutical industry is an important part of China's national economy, with continuous strong demand, need, and capability for innovation. The industry continues to experience high levels of growth. With China's increasing emphasis on the pharmaceutical industry, and the gradual improvement of healthcare policies, momentum supporting the development of China’s pharmaceutical market continues to accelerate. As the sector’s market structure continues to become more optimized, the Chinese pharmaceutical market as a whole has shown a stable and positive pattern, and its current advantages and future potential are also attracting increasing numbers of overseas companies to do business in China.

This article will analyze the Chinese pharmaceutical market from four aspects: a market overview, the regulatory and reimbursement environment, foreign pharmaceutical companies’ strategies in China, and the current state of innovation adoption.


Open PDF

Return to Insights Center

Related Insights

Playbook

Are you using real-world evidence?

Feb 1, 2023

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Blog

Assessing the need for comparative clinical trials in biosimilar development programs

Sep 21, 2023

Video

Creating EU-CTR compliant and patient-friendly lay language summaries (LLS)

Jan 26, 2022

Blog

Biosimilar Development: Are therapeutic clinical trials needed?

Nov 16, 2021

Blog

Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial

Nov 19, 2021

Article

Three strategies for articulating a coherent product value story

Dec 18, 2021

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Blog

Pragmatic Trials: Targeting evidence generation to inform market access and meet payers’ needs

Feb 8, 2022

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022